Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants
Viruses · 2025
DOI: 10.3390/v17010121 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Viruses, 2025. Verfasst von Steven J Smith und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA. Hauptthemen laut MEDLINE: HIV-1, HIV Integrase Inhibitors, HIV Integrase, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, Staff Scientist/Staff Clinician Research Award (SSSC-RA), Intramural Research Program of the NIH, Center for Cancer Research, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Second-generation integrase strand transfer inhibitors (INSTIs) are strongly recommended for people living with HIV-1 (PLWH). The emergence of resistance to second-generation INSTIs has been infrequent and has not yet been a major issue in high-income countries. However, the delayed rollouts of these INSTIs in low- to middle-income countries during the COVID-19 pandemic combined with increased transmission of drug-resistant mutants worldwide are leading to an increase in INSTI resistance. Herein, we evaluated the antiviral potencies of our lead developmental INSTI 4d and the second-generation INSTIs dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB) against a panel of IN quadruple mutants. The mutations are centered around G140S/Q148H, including positions L74, E92, and T97 combined with E138A/K/G140S/Q148H. All of the tested INSTIs lose potency against these IN quadruple mutants compared with the wild-type IN. In single-round infection assays, compound 4d retained higher antiviral potencies (EC50 values) than second-generation INSTIs against a subset of quadruple mutants. These findings may advance understanding of mechanisms that contribute to resistance and, in so doing, facilitate development of new INSTIs with improved antiviral profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
- HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
ORCID-Profile: Steven J Smith, Xue Zhi Zhao, Stephen H Hughes, Terrence R Burke
Förderung
- Intramural NIH HHS
- Staff Scientist/Staff Clinician Research Award (SSSC-RA)
- Intramural Research Program of the NIH, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Zitieren
APA
Smith, S. J., Zhao, X. Z., Hughes, S. H., & Burke, T. R. (2025). Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants. Viruses. https://doi.org/10.3390/v17010121
Vancouver
Smith SJ, Zhao XZ, Hughes SH, Burke TR. Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants. Viruses. 2025. doi:10.3390/v17010121
BibTeX
@article{Smith2025,
author = {Smith, Steven J and Zhao, Xue Zhi and Hughes, Stephen H and Burke, Terrence R},
title = {Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17010121}
}
EUVIMED